National Bank of Canada’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-200
| Closed | -$49 | – | 3319 |
|
|
2026
Q1 | $49 | Hold |
200
| – | – | ﹤0.01% | 2870 |
|
|
2025
Q4 | $84 | Hold |
200
| – | – | ﹤0.01% | 2794 |
|
|
2025
Q3 | $134 | Sell |
200
-30
| -13% | -$16 | ﹤0.01% | 2759 |
|
|
2025
Q2 | $125 | Sell |
230
-2,051
| -90% | -$1.22K | ﹤0.01% | 2847 |
|
|
2025
Q1 | $1.48K | Sell |
2,281
-420
| -16% | -$445 | ﹤0.01% | 2533 |
|
|
2024
Q4 | $2.75K | Buy |
2,701
+2,501
| +1,251% | +$4.57K | ﹤0.01% | 2539 |
|
|
2024
Q3 | $173 | Hold |
200
| – | – | ﹤0.01% | 2535 |
|
|
2024
Q2 | $67 | Hold |
200
| – | – | ﹤0.01% | 2646 |
|
|
2024
Q1 | $110 | Hold |
200
| – | – | ﹤0.01% | 2665 |
|
|
2023
Q4 | $111 | Hold |
200
| – | – | ﹤0.01% | 2652 |
|
|
2023
Q3 | $120 | Hold |
200
| – | – | ﹤0.01% | 2717 |
|
|
2023
Q2 | $260 | Hold |
200
| – | – | ﹤0.01% | 2659 |
|
|
2023
Q1 | $350 | Hold |
200
| – | – | ﹤0.01% | 2614 |
|
|
2022
Q4 | $626 | Hold |
200
| – | – | ﹤0.01% | 2630 |
|
|
2022
Q3 | $1K | Hold |
200
| – | – | ﹤0.01% | 2625 |
|
|
2022
Q2 | $1K | Hold |
200
| – | – | ﹤0.01% | 2716 |
|
|
2022
Q1 | $1K | Hold |
200
| – | – | ﹤0.01% | 2800 |
|
|
2021
Q4 | $2K | Buy |
+200
| New | +$1.74K | ﹤0.01% | 2692 |
|
Other funds holding SGMO
National Bank of Canada's SGMO Position: Q2 2026 in Review
National Bank of Canada sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q2 2026, closing a stake of 200 shares — an estimated $49 sold.
National Bank of Canada first reported a position in SGMO in Q4 2021 and held it in 18 quarters. The position peaked at $2.75K in Q4 2024. 2 funds tracked by Wall St. Rank hold SGMO as of Q2 2026.
- National Bank of Canada reported no remaining SANGAMO THERAPEUTICS INC position as of Q2 2026 after selling out during the quarter.
- National Bank of Canada sold 200 SANGAMO THERAPEUTICS INC shares in Q2 2026, an estimated $49.
- National Bank of Canada first reported a position in SANGAMO THERAPEUTICS INC in Q4 2021 and held it in 18 quarters.
- National Bank of Canada's SANGAMO THERAPEUTICS INC position peaked at $2.75K in Q4 2024.
- 2 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q2 2026.
Based on National Bank of Canada's 13F filing for Q2 2026, filed 10 Aug 2026.